SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the first quarter ended March 31, 2016.
“We have made significant progress in 2016, effectively executing on our clinical development and business strategies,” said M. Scott Salka, CEO of AmpliPhi Biosciences.
“We have made significant progress in 2016, effectively executing on our clinical development and business strategies,” said M. Scott Salka, CEO of AmpliPhi Biosciences.
